Consequently, TF antigen specific therapeutics such as anti-TF antibodies [28] or TF-Ag binding peptides [29] could potentially provide means for targeting simultaneously multiple prostate cancer stem cell subtypes. This evidence concerns the gene TF and prostate carcinoma.